Back to Search
Start Over
In vitro activity of Ceftazidime–Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019.
- Source :
-
Diagnostic Microbiology & Infectious Disease . May2022, Vol. 103 Issue 1, pN.PAG-N.PAG. 1p. - Publication Year :
- 2022
-
Abstract
- ATLAS (Antimicrobial Testing Leadership and Surveillance) detects trends in multi-drug resistance longitudinally over time. In the present study, the in vitro activity of ceftazidime-avibactam and comparators was analyzed against Escherichia coli (n = 458) and Klebsiella pneumoniae (n = 455) isolates obtained from 9 centers across India. The overall susceptibility to ceftazidime-avibactam was observed to be 72% among K. pneumoniae isolates and 87% among E. coli isolates. Among the tested carbapenem resistant isolates, 51% of CR- K. pneumoniae and 24% of CR- E. coli were susceptible to ceftazidime- avibactam. OXA-48 like was identified in 52% of the K. pneumoniae isolates followed by co-production of NDM with OXA-48 like in 27%. NDM was predominantly identified in 68% of the E. coli isolates followed by OXA-48 like in 24% isolates. The findings suggest that ceftazidime- avibactam is a reasonable alternative to standard therapy for management of carbapenem resistant Enterobacterales infections particularly with K. pneumoniae and E. coli with the OXA-48 like genotype. [ABSTRACT FROM AUTHOR]
- Subjects :
- *ESCHERICHIA coli
*COMPARATOR circuits
*MULTIDRUG resistance
*KLEBSIELLA pneumoniae
Subjects
Details
- Language :
- English
- ISSN :
- 07328893
- Volume :
- 103
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Diagnostic Microbiology & Infectious Disease
- Publication Type :
- Academic Journal
- Accession number :
- 156227390
- Full Text :
- https://doi.org/10.1016/j.diagmicrobio.2022.115652